Marpai cut to Hold at Maxim amid capital needs, management changes

Maxim analyst Allen Klee downgraded Marpai to Hold from Buy. The company’s Q3 results exceeded estimates, but the risk of dilution from its upcoming capital needs and the recent management changes balances its attractive technology and market opportunity, the analyst tells investors in a research note. The firm further cites the new management team having suspended guidance, with a call scheduled on 11/29 to discuss the strategic vision and initiatives in place.